Newsroom | 12423 results

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 10 challenged claims of Exact Sciences’ U.S. Patent No. 11,970,746 (the ’746 patent) unpatentable. This decision follows the PTAB’s July 2025 Final Written...

FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health, Inc., announced today that it is initiating a labeling correction which requires a modification of the Owner’s Booklets/System Instructions for Use for all TRUE METRIX, TRUE METRIX AIR, TRUE METRIX GO, and TRUE METRIX PRO Blood Glucose Monitoring Systems (collectively, the “Products”) distributed in the United States, United Kingdom, Mexico, Australia, and the Caribbean. Trividia is updating the E-5 Error Code in the “Messages” section of...

BOSTON--(BUSINESS WIRE)--EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, in collaboration with President Trump’s administration, announced new patient access pathways to make its complete portfolio of infertility medications used for in vitro fertilization (IVF), including Gonal-f® (follitropin alfa for injection), Ovidrel® (choriogonadotropin alfa injection), and Cetrotide® (cetrorelix acetate for injection), more accessible to prescribed infertili...

HOUSTON--(BUSINESS WIRE)--The American Dental Association Foundation (ADAF) is officially kicking off Give Kids A Smile® (GKAS) 2026 at UTHealth Houston School of Dentistry, marking 24 years of transforming children’s lives through this access-to-oral-health-care initiative. What began as a local grassroots movement in St. Louis, MO, has evolved into a national movement, having served more than 10.2 million underserved children since 2003. GKAS begins nationally in February, which is National C...

NEW YORK--(BUSINESS WIRE)--BlinkRx, the leading digital health company transforming access to prescription medications, today announced that former U.S. Senator Joe Manchin has joined the company as a Senior Advisor. BlinkRx also announced that Heather Manchin, a seasoned healthcare executive and former CEO of Mylan, will serve alongside him as a Senior Advisor. Senator Manchin brings decades of bipartisan experience navigating complex policy challenges at the intersection of healthcare, econom...

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 105...

SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, after U.S. markets close. FIGS management will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial and business results and outlook. Prior to the call, FIGS will publish a f...

MINATO-KU, TOKIO, Japan & KOBE, Japan--(BUSINESS WIRE)--Fujirebio Holdings, Inc. (Zentrale: Minato-ku, Tokio; President & CEO: Goki Ishikawa; „Fujirebio“), eine konsolidierte Tochtergesellschaft der H.U. Group Holdings, Inc. (Zentrale: Minato-ku, Tokio; Chairman, President und Group CEO: Shigekazu Takeuchi) und die Sysmex Corporation (Zentrale: Kobe, Japan; President: Kaoru Asano, „Sysmex“) haben eine Vertriebskooperation für Demenztests vereinbart. Diese Vereinbarung ist das Ergebnis fortg...

日本東京港區及神戶--(BUSINESS WIRE)--(美國商業資訊)-- Fujirebio Holdings, Inc.（總公司：日本東京港區；總裁暨執行長：Goki Ishikawa；下稱「Fujirebio」）為H.U. Group Holdings, Inc.（總公司：日本東京港區；董事長、總裁兼集團執行長：Shigekazu Takeuchi）之合併子公司，其與Sysmex Corporation（總公司：日本神戶；總裁：Kaoru Asano；下稱「Sysmex」）已就失智症檢測達成銷售合作協議。此協議係基於雙方於2023年10月簽訂之「免疫分析領域業務合作基本協議」進行持續討論後所促成。1Sysmex將於雙方共同協議之地區與國家，獨家銷售Fujirebio之全自動Lumipulse®免疫分析系統及失智症相關試劑（下稱「本產品」）。未來，Fujirebio與Sysmex將共同合作，以因應治療藥物日益普及所伴隨之檢測需求增長，並將逐步擴展本產品之銷售國家/地區。 自2023年10月簽訂業務合作基本協議以來，雙方持續進行討論，旨在加速免疫分析之發展與全球拓展。2023年11...

MINATO-KU, TÓQUIO, Japão e KOBE, Japão--(BUSINESS WIRE)--A Fujirebio Holdings, Inc. (sede: Minato-ku, Tóquio; presidente e CEO: Goki Ishikawa; “Fujirebio”), uma subsidiária consolidada da H.U. Group Holdings, Inc. (sede: Minato-ku, Tóquio; presidente do conselho, presidente e CEO do grupo: Shigekazu Takeuchi) e a Sysmex Corporation (sede: Kobe, Japão; presidente: Kaoru Asano, “Sysmex”) chegaram a um acordo de colaboração comercial para testes de demência. Este acordo é resultado de discussões c...